When: Close above $285 with momentum confirming

Then: Deploy remaining 25% of target new capital, stop below $281

When: Pullback to $253-255 zone with positive momentum divergence and volume confirmation

Then: Deploy 50% of any incremental capital

When: Weekly close below $258 on volume >7M, OR 30-day alpha drift vs SPY exceeds -0.5%, OR Q3 earnings miss with soft guide

Then: Reassess toward Underweight rating

When: Weekly close below $237 (200 SMA) on volume >7M, OR adverse talc verdict >$5B framework settlement, OR forward EPS revision toward $10-11 invalidating 21.5x forward multiple

Then: Escalate toward Sell rating

HOLD

• MACD collapsed from 8.50 to 1.54 over two and a half months while price carved a marginal new high on September 3rd, the textbook definition of momentum divergence
• PEG of 2.82 based on 41% forward EPS rebound estimate is misleading since 22.3x forward P/E is not cheap for a 5 to 6% grower with beta of 0.235
• JNJ is up 58% trailing twelve months, meaning the defensive rotation has already happened and adding at 270.68 is late positioning
• CAPLYTA Phase 3 hit drove only a 1.7% stock move; TAM expansion is a 2027 to 2028 commercial reality, not a Q4 2026 revenue driver
• Goodwill and intangibles of 96.71 billion dollars represent 48% of total assets, exposing the balance sheet to nine-figure to billion-dollar impairment charges
• Talc litigation is ongoing process with 40,000 plus active claims; new verdicts can move the stock 3 to 5% in a single session
• Entry zone of 265 to 268 with stop at 262.50 creates only 2.50 to 5.50 dollars of risk per share, which is less than one ATR of 5.34, making whipsaw probable
• Target at 285 to 290 offers 17 to 25 dollars of upside but requires six stacked assumptions to align simultaneously

→ vs aggressive: MACD decline from 8.50 to 1.54 over two and a half months is momentum divergence, not healthy digestion; RSI at 56 is neutral, not a buy signal

→ vs aggressive: PEG of 2.82 is not misleading—22.3x forward P/E on 5 to 6% grower with 40,000 plus talc claims is expensive; 41% EPS rebound estimate is consensus guess, not guaranteed outcome

→ vs aggressive: Defensive rotation has already occurred; JNJ up 58% trailing twelve months means easy money is captured; adding at 270.68 is late positioning, not early in the rotation

→ vs aggressive: CAPLYTA TAM expansion is 2027 to 2028 commercial reality, not near-term catalyst; Phase 3 data already priced with only 1.7% stock reaction

→ vs aggressive: ROE of 25.7% is current run rate, not proof of M&A discipline; one data point on 14.5 billion dollar Intra-Cellular bet is insufficient evidence

→ vs aggressive: Talc litigation is not resolved; 2024 charge and 2025 reversal pattern shows active management, not resolution; new bellwether trials can reignite headline risk

→ vs aggressive: Entry at 265 to 268 with stop at 262.50 is less than one ATR of 5.34, creating high probability of getting stopped out on noise before thesis plays out

HOLD with refined laddered add rules, disciplined stops at 263 (daily close basis), and active dividend capture

• Aggressive analyst's 16.4M volume bar is not accumulation—could be rebalancing, index reconstitution, or options dealer hedging, not clean institutional footprint
• PEG normalization using forward 12.14 EPS glosses over that consensus on a stock with 40,000 active litigation claims forecasts legal outcomes not yet determined
• Aggressive analyst's stop at 262.50 is less than one ATR (5.34) with 50 SMA at 263.36—will get triggered by ordinary daily noise
• Conservative analyst's macro framing wrong: defensive rotations in late-cycle are persistent, not exhausted because JNJ is up 58% TTM; flow support continues until rate regime changes
• CAPLYTA dismissal too clean: market prices trial result as reducing execution risk on deployed capital, not just 2027-2028 revenue timeline
• Talc litigation framing overstated: $7B special charges in 2024 and $6B reversal in 2025 shows managed process, not open-ended existential tail risk
• Stop at 263 correct but allow intraday pierce and recovery—only daily close below 263 triggers trim, not any breach
• Add rule should be laddered: 25% tranche on confirmed close above 281 with volume above 10M shares, second 25% on retest of 278-281 holding support, final 25% above 285 with momentum confirming
• Position sizing: benchmark-weight correct, but laddered adds may push slightly above benchmark if all triggers fire—materially overweight is the error, not marginally above
• Dividend: 1.99% yield with 60-plus year hike streak is meaningful total return component on a position of this size
• Alternative flush-add scenario: if 263 breaks and 253-255 prints with positive momentum divergence, neither analyst considering this

→ vs aggressive: Single 16.4M volume day versus 6-8M average is pattern-matching, not data—could be rebalancing, index reconstitution, or options dealer hedging rather than institutional accumulation

→ vs aggressive: Forward 12.14 EPS estimate is consensus on 40,000 active litigation claims—analyst estimates are point estimates on unresolved legal outcomes, not probability-weighted outcomes

→ vs aggressive: Trade structure flawed: 262.50 stop is less than one ATR (5.34) with 50 SMA at 263.36—will be triggered by ordinary daily noise; widening stops breaks reward-to-risk math

→ vs conservative: Macro framing wrong: defensive rotations in late-cycle are persistent once started, not one-and-done events; JNJ being up 58% TTM means it has been a primary vehicle for the flow, not that the flow is exhausted

→ vs conservative: CAPLYTA dismissal too clean: Phase 3 win reduces discount factor on deployed capital and management credibility—market prices reduced execution risk, not just 2027-2028 revenue timeline

→ vs conservative: Talc litigation framing overstated: $7B special charges in 2024 and $6B reversal in 2025 demonstrates actively managed reserve process, not open-ended tail risk requiring prohibition-level positioning